New York · --:-- ET Independent · Not legal or investment advice
Deal Desk

Twelve Term Sheet Red Flags Our Editors Look For First

Most term sheets are reasonable. A few contain clauses that change the shape of the whole deal. Here is the list we check before anything else, and what to say when you find one.

The New York Stock Exchange facade draped with an American flag on Wall Street
Photo: Arild Vågen / Wikimedia Commons (CC BY-SA 4.0) · Image credits

When a draft term sheet arrives, there is a temptation to read it top to bottom like a letter. We suggest a different order. Go straight to the clauses that can turn a fair deal into a painful one, check them first, and only then read the rest. Here is the list our editors use, roughly in order of how much damage each can do.

A red flag is not automatically a deal-breaker. Context matters: a rescue round for a struggling company will look different from a competitive Series A. But each of these deserves a clear explanation from the investor and a conversation with your lawyer.

Economic red flags

1. Participating preferred with no cap

The investor takes its money back and then shares in the rest. In a modest sale, this can cut common holders’ proceeds sharply. Ask for non-participating, or at minimum a cap.

2. A liquidation multiple above 1x

A 2x or 3x preference means investors must receive two or three times their money before common sees anything meaningful in many outcomes. Sometimes it is the price of a high headline valuation. Do the maths both ways.

3. Cumulative dividends

Dividends that accrue every year, even if never paid, and are added to the preference quietly inflate what investors take in a sale. Rare in early-stage US deals; worth questioning when you see them.

4. Full-ratchet anti-dilution

Any future sale of stock below this round’s price resets the conversion price all the way down. Broad-based weighted average is the market standard.

5. An oversized option pool inside the pre-money

A 20 percent pool you do not need is simply a lower valuation in disguise. Size it to a credible hiring plan.

6. Redemption rights

The right to force the company to buy back shares after a few years can create a cash demand the company cannot meet. Uncommon in US venture today, though more frequent in some other markets.

Control red flags

7. Investor control of the board at an early stage

Ceding board control at seed or Series A is unusual. It means founders can be replaced, budgets rejected and a sale approved without their support.

8. Protective provisions that reach into operations

Vetoes over the sale of the company and new senior stock are normal. Vetoes over hiring, budgets, product launches or contracts above a low threshold are not. Those belong to the board.

9. A drag-along triggered by preferred alone

If investors can force a sale without the board or common holders, founders may be dragged into a deal that mostly pays back preferences. Ask for board and common consent, and the standard protections for dragged holders.

10. Founder re-vesting with no credit for time served

Restarting a four-year clock on shares founders have already earned, without acknowledging years of work, is a meaningful transfer of value. Negotiate credit, and double-trigger acceleration.

Process red flags

11. An exploding deadline

“Sign by Friday or the offer lapses.” Sometimes there is a real reason, such as a partnership meeting or a fund closing. Often it is pressure designed to stop you speaking to anyone else. A reasonable investor will usually give you a few days to take advice.

12. A long no-shop with uncapped expenses

Sixty or ninety days of exclusivity, combined with an obligation to pay the investor’s legal bills whether or not the deal closes, puts all the risk of a collapse on the company.

You seeA reasonable counter
Participating, uncapped1x non-participating, or participation capped at 2–3x
2x preference1x, or 1x plus a smaller valuation concession
Full ratchetBroad-based weighted average
20% pool in pre-moneyA pool sized to an 18-month hiring plan
Investor board control at Series A2 common, 2 investor, 1 mutually agreed independent
60-day no-shop, uncapped fees30–45 days, capped fees payable at closing

The red flag that is not in the document

The most important term in any venture deal is the person who will sit on your board. Before signing, speak to founders that investor has backed, especially founders whose companies struggled. Ask what happened when things went badly: whether the investor supported a bridge round, how they behaved in a down round, whether they were honest. No clause protects you from a bad partner as well as a good reference call does.

“Market standard” is a phrase, not an argument. Ask which deals, which year and which stage.

How to raise a concern without souring the relationship

  1. Ask the investor to explain the reason for the term. Sometimes there is a specific worry you can address another way.
  2. Let your lawyer carry the technical arguments. It keeps the founder–investor relationship cleaner.
  3. Trade, do not just demand. Accepting a slightly lower valuation in exchange for clean terms is often a good deal.
  4. Prioritise. Pick the two or three issues that matter most and concede the rest.

Sources and further reading

Compiled by Term Sheet editors from the NVCA model documents, published commentary by venture lawyers and investors, and the other guides on this site. Suggested counters are common negotiating positions, not legal advice for any specific deal.

Before you signThis guide is general education, not legal advice. Market terms vary by country, stage and sector, and every deal is different. Have a qualified startup lawyer review any term sheet before you sign it.

Educational content only. Term Sheet is an independent publication. Nothing here is legal, tax or investment advice, and reading it does not create an attorney–client relationship. Talk to a qualified lawyer before you sign anything. We are not affiliated with any law firm, venture fund, bank, trade association or other publication using a similar name.